A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)

Launched by JANSSEN RESEARCH & DEVELOPMENT, LLC · Mar 22, 2021

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called bleximenib for patients with acute leukemia, which includes types like acute myeloid leukemia and acute lymphoblastic leukemia. The main goal is to find the best dose of bleximenib that is safe and effective for patients who have either not responded to other treatments or have run out of treatment options. The trial is divided into two parts: the first part focuses on finding the right dose, while the second part will look at how well the treatment works at that dose.

To be eligible for this trial, participants need to be at least 12 years old and have a specific type of acute leukemia that has certain genetic changes. Adults over 18 can also participate if they have been diagnosed with acute myeloid leukemia. Participants will undergo regular monitoring to ensure their safety while receiving the treatment. This trial is currently recruiting participants, and it's important to note that individuals with certain medical conditions or previous treatments may not be able to join. If you or a loved one are considering participating, you can expect close support from the research team throughout the study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• Phase 1:
• • Age 2 years and above (pediatric cohort only), all other cohorts 18 years and above
• • Relapsed or refractory (R/R) acute leukemia and has exhausted, or is ineligible for, available therapeutic options
• • Acute leukemia harboring histone-lysine N-methyltransferase 2A (KMT2A), nucleophosmin 1 gene (NPM1) or nucleoporin 98 gene or nucleoporin 214 gene (NUP98 or NUP214) alterations
• • Phase: 2
• • Participants greater than 18 years are eligible
• • Must have had an initial diagnosis of acute myeloid leukemia (AML) per the WHO 2022 classification criteria and have relapsed/refractory disease
• • AML harboring KMT2A-r (gene rearrangement/translocation) or NPM1 mutations only
• For Both Phase 1 and 2:
• • Pretreatment clinical laboratory values meeting the following criteria: (a) Hematology: white blood cell (WBC) count less than or equal to (\<=) 20\*10\^9/liter (L) and (b) renal function; For adult participants, estimated or measured glomerular filtration rate greater than equal (\>=) 30 milliliter per minute (mL/min) per four variable MDRD equation. For pediatric participants an estimated or measured glomerular filtration rate \>40 mL/min per the CKiD (Chronic Kidney Disease in Children) Schwartz formula
• • Eastern Cooperative Oncology Group (ECOG) performance status grade of 0, 1 or 2. Pediatric participants only: Performance status \>=70 by Lansky scale (for participants less than \[\<\]16 years of age) or \>=70 Karnofsky scale (for participants \>=16 years of age)
• • A female of childbearing potential must have a negative highly sensitive serum beta-human chorionic gonadotropin at screening and within 48 hours prior to the first dose of study treatment
• • Participant must agree to all protocol required contraception requirements and avoid sperm or egg donations or freezing for future reproductive use while on study and for 90 days (males) or 6 months (females) after the last dose of study treatment
• Exclusion Criteria:
• • Acute promyelocytic leukemia, diagnosis of Down syndrome associated leukemia or juvenile myelomonocytic leukemia according to World Health Organization (WHO) 2016 criteria
• • Active central nervous system (CNS) disease
• • Prior solid organ transplantation
• • QTc according to Fridericia's formula (QTcF) for males \>= 450 millisecond (msec) or for females \>= 470 msec. Participants with a family history of Long QT syndrome are excluded
• • Exclusion criteria related to stem cell transplant: a. Received prior treatment with allogenic bone marrow or stem cell transplant \<=3 months before the first dose of study treatment; b. Has evidence of graft versus host disease; c. Received donor lymphocyte infusion \<=1 month before the first dose of study treatment; d. Requires immunosuppressant therapy (exception: daily doses \<=10 milligrams (mg) prednisone or equivalent are allowed for adrenal replacement)
• • Prior cancer immunotherapy within 4 weeks prior to enrollment or blinatumomab within 2 weeks prior to enrollment. Additional prior cancer therapies must not be given within 4 weeks prior to enrollment or 5 half-lives of the agent (whichever is shorter)